Company

Diamyd Medical AB

Headquarters: Stockholm, Sweden

Employees: 19

CEO: Mr. Ulf Hannelius

OMX: DMYD.B

Market Cap

kr1.34 Billion

SEK as of July 1, 2024

US$126.1 Million

Market Cap History

Diamyd Medical AB market capitalization over time

Evolution of Diamyd Medical AB market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Diamyd Medical AB

Detailed Description

Diamyd Medical AB (publ) develops therapies for the treatment of autoimmune diabetes. The company develops Diamyd, an antigen-specific immunotherapy diabetes vaccine, which is in phase IIb clinical trial for the treatment of type 1 diabetes and latent autoimmune diabetes; and Remygen, an oral regenerative and immunomodulatory drug candidate, which is in phase I/II clinical trial for the treatment of autoimmune and type 2 diabetes. The company was formerly known as Diamyd Therapeutics AB and changed its name to Diamyd Medical AB (publ) in April 2013. Diamyd Medical AB (publ) was incorporated in 1984 and is based in Stockholm, Sweden.

Top 1-year algo backtest: +227.67%

$10,000 in September 2023 would now be $32,767 by following this algorithm daily at market close.

Use AI to boost your investing & swing trading, now!

Try Disfold DeepFinance FREE

Stocks & Indices

Diamyd Medical AB has the following listings and related stock indices.


Stock: OMX: DMYD.B wb_incandescent

Stock: FSX: DMN wb_incandescent

Details

Headquarters:

Kungsgatan 29

Stockholm, 111 56

Sweden

Phone: 46 86 61 00 26

Fax: 46 86 61 63 68